The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Open accessAbstract
The development of targeted medicine has greatly expanded treatment options and spurred new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging as a prevalent treatment in recent years. With mixed clinical success, mAbs still hold significant shortcomings, as they possess limited tumor penetration, high manufacturing costs, and the potential to develop therapeutic resistance. However, the recent discovery of "nanobodies," the smallest-known functional antibody fragment, has demonstrated significant translational potential in preclinical and clinical studies. This review highlights their various applications in cancer and analyzes their trajectory toward their translation into the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–212 of 212
A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity
Deng, W., Liu, J., Pan, H., Li, L., Zhou, C., Wang, X., Shu, R., Dong, B., Cao, D., Li, Q., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000200 · Cited by 17
Intracellular displacement of p53 using transactivation domain (p53 TAD) specific nanobodies
Steels, A., Verhelle, A., Zwaenepoel, O., & Gettemans, J. (2018) · mAbs · doi:10.1080/19420862.2018.1502025 · Cited by 17
Bakherad, H., Gargari, S. L. M., Sepehrizadeh, Z., Aghamollaei, H., Taheri, R. A., Torshabi, M., Yazdi, M. T., Ebrahimizadeh, W., & Setayesh, N. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.025 · Cited by 16
Crowley, S. J., Bruck, P. T., Bhuiyan, A. M., Mitchell-Gears, A., Walsh, M. J., Zhangxu, K., Ali, L. R., Jeong, H., Ingram, J. R., Knipe, D. M., et al. (2020) · Open Biology · doi:10.1098/rsob.190235 · Cited by 16
Nb-induced stabilisation of p53 in HPV-infected cells
Steels, A., Vannevel, L., Zwaenepoel, O., & Gettemans, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-49061-9 · Cited by 15
Sadeghian-Rizi, T., Behdani, M., Khanahmad, H., Hamid, M., & Jahanian‐Najafabadi, A. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666181114134518 · Cited by 14
Zhu, H., Zhao, L., Li, Z., Wen, B., Qiu, C., Liu, M., Xu, Z., Hu, S., & Li, H. (2019) · Protein Expression and Purification · doi:10.1016/j.pep.2019.02.003 · Cited by 14
Engineering of Nanobodies Recognizing the Human Chemokine Receptor CCR7
Jakobs, B. D., Spannagel, L., Purvanov, V., Allmen, E. U.-V., Matti, C., & Legler, D. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102597 · Cited by 14
Zhu, A., Sha, H., Su, S., Chen, F., Wei, J., Meng, F., Yang, Y., Du, J., Shao, J., Ji, F.-Z., et al. (2018) · PubMed · Cited by 13
Shoae‐Hassani, A., Mortazavi‐Tabatabaei, S. A., Sharif, S., Madadi, S., Rezaei-Khaligh, H., & Verdi, J. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0206-x · Cited by 12
Targeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target
Rashidi, S. K., Gargari, S. L. M., & Ebrahimizadeh, W. (2017) · Iranian Journal of Biotechnology · doi:10.15171/ijb.1472 · Cited by 9
Stimulation of Camel Polyclonal Antibody against Human T cell Immunoglobulin and Mucin 3
Homayouni, V., Khanahmad, H., Ganjalıkhani-Hakemi, M., Behdani, M., Ghasemi, P., & Rezaei, A. (2017) · Iranian Journal of Biotechnology · doi:10.15171/ijb.1427 · Cited by 6
Cited by
Engineering protein-based therapeutics through structural and chemical design
Ebrahimi, S. B., & Samanta, D. (2023) · Nature Communications · doi:10.1038/s41467-023-38039-x · Cited by 382
NANOBODIES®: A Review of Diagnostic and Therapeutic Applications
Jin, B.-K., Odongo, S., Radwanska, M., & Magez, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065994 · Cited by 371
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
Abanades, B., Wong, W. K., Boyles, F., Georges, G., Bujotzek, A., & Deane, C. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04927-7 · Cited by 298
Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation
Zhang, H., Han, Y., Yang, Y., Lin, F., Li, K., Kong, L., Liu, H., Dang, Y., Lin, J., & Chen, P. R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08521 · Cited by 292
Structural Modeling of Nanobodies: A Benchmark of State-of-the-Art Artificial Intelligence Programs
(2023) · doi:10.3390/molecules28103991 · Cited by 39
Metadata
- Authors
- Yang, E. Y., & Shah, K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-23
- Volume
- 10
- Pages
- 1182-1182
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3044721763
- Cited by
- 291
- References
- 212
- FWCI
- 20.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.